This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD36 / SR-B3 Protein, His Tag
catalog :
CD6-H5221
quantity :
500 ug, 100 ug
price :
900 USD, 260 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CD6-H5221
product name :
Human CD36 / SR-B3 Protein, His Tag
quantity :
500 ug, 100 ug
price :
900 USD, 260 USD
quantity & price :
$260/100ug,$900/500ug
target :
CD36
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CD36, His Tag (CD6-H5221) is expressed from human 293 cells (HEK293). It contains AA Gly 30 - Asn 439 (Accession # NP_001001547.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD36, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
CD36 (Cluster of Differentiation 36) is also known as platelet membrane glycoprotein IV (GPIV), fatty acid translocase (FAT), thrombospondin receptor, collagen receptor, and scavenger receptor class B, member 3 (SRB3), is a member of the class B scavenger receptor family of cell surface proteins. The human CD36 gene encodes a single chain 472 amino acid residue protein containing both an N- and a C-terminal cytoplasmic tail and an extracellular loop.CD36 is found on platelets, erythrocytes, monocytes, differentiated adipocytes, mammary epithelial cells, spleen cells and some skin microdermal endothelial cells. CD36 is a multiligand pattern recognition receptor that interacts with a large number of structurally dissimilar ligands, including long chain fatty acid (LCFA), advanced glycation end products (AGE), thrombospondin-1, oxidized low-density lipoproteins (oxLDLs), high density lipoprotein (HDL), phosphatidylserine, apoptotic cells, beta-amyloid fibrils (fAβ), collagens I and IV, and Plasmodium falciparum infected erythrocytes. CD36 is required for the anti-angiogenic effects of thrombospondin1 In the corneal neovascularization assay. On binding a ligand the protein and ligand are internalized. This internalization is independent of macropinocytosis and occurs by an actin dependent mechanism requiring the activation Src-family kinases, JNK and Rho-family GTPases. CD36 ligands have also been shown to promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.
References :
(1) Husemann, J. et al., 2002, Glia 40:195.
(2) Armstrong, L and P. Bornstein, 2003, Matrix. Biol. 22:63.
(3) Collins RF, et al., 2009, J. Biol. Chem. 284 (44): 30288–97.
(4) Stewart CR, et al., 2010, Nat. Immunol. 11 (2): 155–61.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments